|
|
 |
 |
Novel anti-metastatic treatments |
|
Cancer affects one in three individuals and is the leading cause of death below the age of 75 in most Western countries. Enormous efforts have been focused on improving diagnostics and therapeutics for cancer. However, the overall mortality rates remain virtually constant. |
The primary tumour is rarely the cause of death of cancer patients. In fact, in the vast majority of cases, cancer-associated mortality is the result of cancer cell dissemination to other organs, i.e. metastasis. The inherent problem with most current therapeutic approaches is their failure to target the dissemination process. |
Present share price
|
||||||||||||||
Wnt-5a negative and positive tumour cells |
WntResarch at a glance WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007. The focus and aim of WntResearch is to develop novel anti-metastatic therapies for the treatment of cancer patients meets a large unmet medical need. The company has two projects Foxy-5 and Box-5. The lead project is Foxy-5 which is currently being tested in vivo models and is planned to enter and finalize phase 1 clinical trials in metastatic cancer in 2012. |
The amounts of funding from the Eurostars program now decided for the Foxy-5 project GEM deal in place to support the Foxy-5 program |
||||||||||||||
